Simplify Logo

Full-Time

Vice President of Market Access and Public Policy

Confirmed live in the last 24 hours

Beam Therapeutics

Beam Therapeutics

201-500 employees

Develops precision genetic medicines using base editing

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Category
Strategy Development
Business Development
Business & Strategy
Required Skills
Public Policy
Requirements
  • BS/BA degree in business or related discipline. Advanced degree in Public Health, Health Policy, Business Administration, or a related field preferred.
  • 20 or more years experience within the pharmaceutical or biotechnology industries, 7 or more of which in market access leadership roles.
  • Launch experienced strongly preferred (US and or global)
  • Experience in public policy, or government affairs within the pharmaceutical or biotechnology industry, with a strong focus on rare diseases is highly preferred.
  • In-depth knowledge of the healthcare system, pricing and reimbursement processes, billing and coding processes, and regulatory landscape. Experience in rare disease markets or cell and gene therapy is preferred.
  • Established network within the healthcare industry, including government agencies, and payers
  • Experience leading internal, remote and field based teams with a proven track record of successfully delivering results in a positive, collaborative and compliant way with the ability to inspire and develop talent.
  • Strong analytical and strategic thinking abilities, with a proven track record of developing and implementing successful market access strategies.
  • Excellent verbal and written communication skills, with the ability to effectively engage and influence a wide range of stakeholders.
  • Willingness to travel domestically and internationally as needed (up to 25%) to meet with stakeholders and attend industry events.
Responsibilities
  • Develop and execute comprehensive market access strategies to ensure optimal pricing, reimbursement, and market entry for our portfolio, with a strong focus on rare diseases.
  • Shape and influence public policy to support favorable regulatory and legislative environments for our products. Monitor and analyze policy trends and advocate for policies that align with company goals.
  • Build and maintain relationships with government officials, regulatory agencies, and industry associations to advance our legislative and regulatory priorities.
  • Collaborate with internal and external stakeholders, including payers, providers, patient advocacy groups, and industry partners, to drive market access initiatives and support patient access to therapies.
  • Work closely with other departments, including Commercial, Medical Affairs, Regulatory, and Legal, to align market access strategies with broader business objectives.
  • Lead overall Market Access and Public Policy for Beam globally, with an initial focus on the US and major European Markets.

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise modifications to the genetic code to potentially correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures instead of temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and future commercialization of their treatments. Unlike many competitors, Beam Therapeutics emphasizes collaboration with pharmaceutical companies and research institutions, which helps them secure funding and advance their projects. Their goal is to advance scientific research and deliver effective, long-lasting treatments for patients.

Company Stage

IPO

Total Funding

$689M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

4%

1 year growth

-8%

2 year growth

-7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Beam Therapeutics' innovative base editing technology has the potential to revolutionize the treatment of genetic disorders, offering hope for lifelong cures.
  • The company's strong pipeline, including early-stage studies for sickle cell disease, positions it well for future growth and breakthroughs.
  • Significant investments and partnerships, like the recent $250 million deal with Eli Lilly, enhance Beam's financial stability and research capabilities.

What critics are saying

  • The recent retirement of CFO Terry-Ann Burrell and the layoff of 20% of staff could lead to operational disruptions and affect company morale.
  • Beam's focus on early-stage studies means that its treatments are still years away from commercialization, posing a risk to short-term revenue generation.

What makes Beam Therapeutics unique

  • Beam Therapeutics leverages base editing technology, which allows for precise genetic modifications, setting it apart from traditional gene-editing methods like CRISPR.
  • The company's focus on developing lifelong cures for genetic disorders, rather than temporary treatments, distinguishes it in the biotechnology sector.
  • Beam's strategic partnerships and licensing agreements, such as the $250 million deal with Eli Lilly, provide significant financial backing and collaborative opportunities.

Help us improve and share your feedback! Did you find this helpful?